Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
52.85 USD
↘ 0.55 (1.03%)AT CLOSE (11:59 AM EDT)
51.97
↘ 0.88 (1.66%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
51.97
↘ 0.88 (1.66%)
🔴Market: CLOSED
Open?$52.40
High?$53.02
Low?$52.04
Prev. Close?$53.40
Volume?4.3M
Avg. Volume?3.3M
VWAP?$52.58
Rel. Volume?1.30x
Bid / Ask
Bid?$49.96 × 100
Ask?$54.79 × 100
Spread?$4.83
Midpoint?$52.38
Valuation & Ratios
Market Cap?23.4B
Shares Out?443.3M
Float?406.4M
Float %?94.9%
P/E Ratio?28.32
P/B Ratio?3.40
EPS?$1.87
Dividend?3.14%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
23.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.66Strong
Quick Ratio?2.66Strong
Cash Ratio?1.09Strong
Debt/Equity?1.30Moderate
ValuationRICHLY VALUED
Score
47/100
P/E?
28.3FAIR▾
P/B?
3.40FAIR▾
P/S?
9.60HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
21.6HIGH▾
EV/Sales?
13.04HIGH▾
Returns & Efficiency
ROE?
12.0%STRONG▾
ROA?
4.2%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$31.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist